NLTX NASDAQ
Neoleukin Therapeutics, Inc.
1W: +5.8%
1M: +4.2%
3M: -5.9%
1Y: +60.1%
3Y: -94.4%
5Y: -69.8%
$3.49
Last traded 2023-12-19 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$8.2M
52W Range3.42-18.8
Volume109,095
Avg Volume6,085
Beta1.10
Dividend—
Analyst Ratings
Company Info
CEODonna M. Cochener-Metcalfe
Employees7
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2014-03-07
Websiteneoleukin.com
188 East Blaine Street
Seattle, WA 98102
US
Seattle, WA 98102
US
855 226 6447
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Woods Robert Keith | A-Award | 15,400 | $32.30 | 2024-01-16 |
| PALEKAR ROHAN | A-Award | 15,400 | $32.30 | 2024-01-16 |
| Noonberg Sarah B. | A-Award | 15,400 | $32.30 | 2024-01-16 |
| Freedland Cory S. | A-Award | 15,400 | $32.30 | 2024-01-16 |
| BAFFI ROBERT | A-Award | 15,400 | $32.30 | 2024-01-16 |